CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2, Open-Label, Dose Escalation and Expansion Study With PT886 Followed by a Multi-cohorT Study in Patients With Advanced Gastrointestinal Cancers, Including GastrIc, Gastroesophageal JuNction, Pancreatic Ductal or Biliary Tract AdEnocarcinomas of PT886, in Combination With ChemotherApy, Targeted Therapy, and/or an Immune ChecKpoint Inhibitor. The TWINPEAK Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05482893
Title field or adapter rule: {'original_value': 'A Phase 1/2, Open-Label, Dose Escalation and Expansion Study With PT886 Followed by a Multi-cohorT Study in Patients With Advanced Gastrointestinal Cancers, Including GastrIc, Gastroesophageal JuNction, Pancreatic Ductal or Biliary Tract AdEnocarcinomas of PT886, in Combination With ChemotherApy, Targeted Therapy, and/or an Immune ChecKpoint Inhibitor. The TWINPEAK Study', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:24.837249+00:00
Published At: 2026-09-28T00:00:00+00:00
Record Updated At: 2026-09-28
Source Retrieved At: 2026-10-31T22:17:54.613222+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Gastric or Gastroesophageal Junction Adenocarcinoma", "Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancer (BTC)", "Colorectal Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-09-28", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT05482893"
protocolSection.identificationModule.officialTitle: "A Phase 1/2, Open-Label, Dose Escalation and Expansion Study With PT886 Followed by a Multi-cohorT Study in Patients With Advanced Gastrointestinal Cancers, Including GastrIc, Gastroesophageal JuNction, Pancreatic Ductal or Biliary Tract AdEnocarcinomas of PT886, in Combination With ChemotherApy, Targeted Therapy, and/or an Immune ChecKpoint Inhibitor. The TWINPEAK Study"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

Study condition terms

Interventions recorded in this study

{'armGroupLabels': ['Combination Expansion with Chemotherapy or Targeted Therapy', 'Combination Expansion with KEYTRUDA® (pembrolizumab)', 'Dose Escalation', 'Dose Expansion'], 'description': 'Spevatamig (PT886) monotherapy, a novel bispecific antibody that targets Claudin 18.2 and CD47.', 'name': 'Spevatamig (PT886)', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Combination Expansion with Chemotherapy or Targeted Therapy'], 'description': 'Chemotherapy as a combination partner to Spevatamig (PT886) in Part C: substudy C1', 'name': 'Paclitaxel', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Combination Expansion with Chemotherapy or Targeted Therapy'], 'description': 'Chemotherapy as a combination partner to Abraxane and Spevatamig (PT886) in Part C: substudy C2', 'name': 'Gemcitabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Combination Expansion with Chemotherapy or Targeted Therapy'], 'description': 'Chemotherapy as a combination partner to Gemcitabine and Spevatamig (PT886) in Part C: substudy C2', 'name': 'Abraxane', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Combination Expansion with KEYTRUDA® (pembrolizumab)'], 'description': 'Immune checkpoint inhibitor as a combination partner to Spevatamig (PT886) in Part D.', 'name': 'KEYTRUDA® (pembrolizumab)', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Combination Expansion with Chemotherapy or Targeted Therapy', 'Combination Expansion with KEYTRUDA® (pembrolizumab)'], 'description': 'Chemotherapy as a combination partner to Spevatamig (PT886) and KEYTRUDA® (pembrolizumab, Part D only)', 'name': 'FOLFOX', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Combination Expansion with KEYTRUDA® (pembrolizumab)'], 'description': 'Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and Spevatamig (PT886)', 'name': 'CAPOX', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Combination Expansion with Chemotherapy or Targeted Therapy'], 'description': 'Chemotherapy as a combination partner to Spevatamig (PT886) in Part C: substudy C3', 'name': 'FOLFIRINOX', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Combination Expansion with Chemotherapy or Targeted Therapy'], 'description': 'Chemotherapy as a combination partner to Spevatamig (PT886) in Part C: substudies C5 and C7.', 'name': 'TAS 102', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Combination Expansion with Chemotherapy or Targeted Therapy'], 'description': 'Targeted therapy as a combination partner to Spevatamig (PT886) in Part C: substudies C6 and C7.', 'name': 'Bevacizumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Combination Expansion with KEYTRUDA® (pembrolizumab)'], 'description': 'Chemotherapy as a combination partner to Spevatamig (PT886) and KEYTRUDA® (pembrolizumab) in Part D: substudy D2', 'name': 'Gemcitabine Combined With Cisplatin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Combination Expansion with Chemotherapy or Targeted Therapy'], 'description': 'Chemotherapy as a combination partner to Spevatamig (PT886) in Part C: substudy C3.', 'name': 'NALIRIFOX', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.